Exelixis Inc (EXEL)
23.71
+0.42
(+1.80%)
USD |
NASDAQ |
Apr 24, 16:00
23.70
0.00 (0.00%)
After-Hours: 20:00
Exelixis Cash from Financing (TTM): -546.05M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -546.05M |
| September 30, 2023 | -341.88M |
| June 30, 2023 | -124.25M |
| March 31, 2023 | 4.967M |
| December 31, 2022 | 0.586M |
| September 30, 2022 | -15.40M |
| June 30, 2022 | -16.25M |
| March 31, 2022 | -11.95M |
| December 31, 2021 | -14.80M |
| September 30, 2021 | -15.50M |
| June 30, 2021 | -16.06M |
| March 31, 2021 | -29.93M |
| December 31, 2020 | -25.13M |
| September 30, 2020 | -9.438M |
| June 30, 2020 | -2.729M |
| March 31, 2020 | 9.472M |
| December 31, 2019 | 12.55M |
| September 30, 2019 | 14.41M |
| June 30, 2019 | 14.75M |
| March 31, 2019 | 15.17M |
| December 31, 2018 | 9.691M |
| September 30, 2018 | 10.12M |
| June 30, 2018 | 9.382M |
| March 31, 2018 | -98.31M |
| December 31, 2017 | -169.93M |
| Date | Value |
|---|---|
| September 30, 2017 | -153.45M |
| June 30, 2017 | -157.02M |
| March 31, 2017 | -54.30M |
| December 31, 2016 | 15.70M |
| September 30, 2016 | 6.81M |
| June 30, 2016 | 156.95M |
| March 31, 2016 | 150.55M |
| December 31, 2015 | 152.21M |
| September 30, 2015 | 145.46M |
| June 30, 2015 | -4.351M |
| March 31, 2015 | -0.012M |
| December 31, 2014 | 65.49M |
| September 30, 2014 | 65.15M |
| June 30, 2014 | 64.73M |
| March 31, 2014 | 64.39M |
| December 31, 2013 | -11.67M |
| September 30, 2013 | -11.83M |
| June 30, 2013 | 404.89M |
| March 31, 2013 | 404.20M |
| December 31, 2012 | 478.43M |
| September 30, 2012 | 478.64M |
| June 30, 2012 | 64.36M |
| March 31, 2012 | 71.58M |
| December 31, 2011 | 187.51M |
| September 30, 2011 | 162.12M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-546.05M
Minimum
Dec 2023
14.75M
Maximum
Jun 2019
-58.56M
Average
-14.80M
Median
Dec 2021
Cash from Financing (TTM) Benchmarks
| Regeneron Pharmaceuticals Inc | -1.790B |
| Bristol-Myers Squibb Co | -9.416B |
| Johnson & Johnson | -15.82B |
| Bio-Techne Corp | 116.73M |
| Legend Biotech Corp | 791.49M |